Offshore oil and gas modular equipment provider VME (VME.US) rushes toward Nasdaq, plans to raise up to $30 million.
Offshore oil and gas process modules and separation equipment provider VME Companies has applied for a Nasdaq IPO, planning to raise up to $30 million, with Kingswood as sole bookrunner.
VME Companies, a supplier of process modules and separation equipment for offshore oil and gas facilities, filed with the SEC on Friday to raise up to $30 million through an IPO.
VME Companies designs, manufactures, and delivers engineered process modules and packaged equipment for offshore and onshore energy projects. Its EPC & Modular Solutions segment provides integrated design, procurement, and construction services for modular process systems used in floating production storage and offloading (FPSO) vessels, mobile offshore production units, and fixed platforms, covering oil and gas separation, produced water treatment, and gas compression; the company has supplied modules for more than 60 FPSOs, and this segment accounts for approximately 80% to 90% of its sales. Its Separation Technologies segment supplies separation internals, pressure vessels, treatment systems, and packaged pump sets to upstream, midstream, and downstream customers.
The Taylor, Texas-based company was founded in 1985. It plans to list on Nasdaq under the ticker VME. VME Companies previously filed confidentially on July 2, 2026. Kingswood Capital Markets is the sole bookrunner for the deal. Pricing terms for the offering were not disclosed.
Related Articles

Hefei Lifeon Pharmaceutical (003020.SZ): Marketing application for dexmethylphenidate hydrochloride API approved

ZhuZhou QianJin Pharmaceutical (600479.SH): Ferrous Succinate Tablets and Escitalopram Oxalate Tablets Obtain Drug Registration Certificates

Kexing Biopharm (688136.SH): GB20 Injection Receives Drug Clinical Trial Approval Notice
Hefei Lifeon Pharmaceutical (003020.SZ): Marketing application for dexmethylphenidate hydrochloride API approved

ZhuZhou QianJin Pharmaceutical (600479.SH): Ferrous Succinate Tablets and Escitalopram Oxalate Tablets Obtain Drug Registration Certificates

Kexing Biopharm (688136.SH): GB20 Injection Receives Drug Clinical Trial Approval Notice

RECOMMEND





